When Animal Testing Failed
Case studies of drugs that passed animal safety tests but caused serious harm to humans—and how human-relevant methods could have predicted these disasters
Major Drug Disasters
These drugs passed extensive animal testing yet caused catastrophic harm to humans
Passed safety tests in rodents with no signs of teratogenicity. Marketed as safe for pregnant women for morning sickness.
Caused severe birth defects (phocomelia) in over 10,000 children worldwide. Limb malformations, organ damage, and deaths.
Human placental organoids and iPSC-derived embryoid bodies would show teratogenic effects on human cells.
Safe in cynomolgus monkeys at 500x the human dose. No adverse effects observed in extensive primate studies.
All 6 volunteers suffered catastrophic cytokine storm within hours. Multi-organ failure, ICU admission, permanent injuries.
Human immune cells in vitro would have shown the massive cytokine release response to this CD28 superagonist.
No cardiovascular toxicity detected in preclinical animal studies. Appeared safe and effective for arthritis pain.
Caused an estimated 60,000+ heart attacks and strokes before withdrawal. 3x increased cardiovascular risk.
Human heart-on-chip with vascular endothelium could model prothrombotic effects of COX-2 inhibition.
Safe in mice, rats, dogs, and monkeys for up to 3 months of treatment. No liver toxicity observed.
5 of 15 patients died from liver failure. 2 required emergency liver transplants. Mitochondrial toxicity.
Human hepatocyte cultures and liver-on-chip show mitochondrial toxicity with human-specific transporters.
Minimal liver toxicity signals in animal studies. Approved for type 2 diabetes treatment.
Caused severe hepatotoxicity. 63 confirmed deaths from liver failure. Withdrawn from market in 2000.
Human liver organoids and hepatocyte chips detect idiosyncratic hepatotoxicity missed by animal models.
Safe in mice, rats, dogs, and monkeys at much higher doses than planned for humans.
1 volunteer died, 5 hospitalized with brain damage during Phase 1 trial. Irreversible neurological injury.
Human brain organoids and BBB-on-chip could reveal off-target effects on human neural tissue.
How NAMs Could Prevent Future Disasters
Human-relevant testing methods detect toxicity that animal models miss
✓ Human Liver-on-Chip
Detects hepatotoxicity with human CYP450 enzymes and bile transporters—catches drugs like FIAU and Rezulin.
✓ Human Heart-on-Chip
Reveals cardiotoxicity and arrhythmia risk using human cardiomyocytes—would have flagged Vioxx.
✓ Human Immune Cells
Tests cytokine release and immune activation in human cells—would have prevented TGN1412 disaster.
✓ Brain Organoids
Models human neural tissue responses to drugs—could detect neurotoxicity like BIA 10-2474.
✓ Placental Models
Tests drug transfer and teratogenicity in human placental tissue—would catch thalidomide-type effects.
✓ Patient iPSC Models
Tests drugs on cells from diverse patient populations—reveals idiosyncratic and genetic-specific toxicity.